33 results about "Tissue transplantation" patented technology

1. The name of the design product: medical stirring and mixing container. 2. The use of the design product: for containing materials to be stirred and mixed, such as medical tissue transplantation materials, to be stirred and mixed to synthesize composite medical tissue transplantation materials. 3. The design points of the design product: in shape. 4. The picture or photo best showing the design points: perspective view 1.

This invention discloses a parathyroid tissue transplantation device, belonging to the field of transplantation device technology, including a syringe, a cutting device, and a pusher. The cutting device has the same size as the inner wall of the syringe, and a through groove runs through the top surface of the cutting device. A material hopper is installed in the through groove, and the bottom surface of the material hopper is equipped with dense blades. A squeezing rod is placed in the material hopper, and a pusher plate is fixed at one end of the squeezing rod. The pusher plate has the same size as the inner wall of the material hopper. A drive component is installed inside the cutting device, which controls the rotation of the cutting blades. By setting up the syringe, cutting device, and pusher, the parathyroid tissue can be efficiently processed into a homogenate, realizing seamless linkage of tissue loading, cutting, and pushing. The entire process is completed in a closed structure, reducing tissue exposure, contamination, and residual loss. It realizes an integrated operation of immediate harvesting, processing, and transplantation during surgery, greatly improving the operation efficiency, standardization, and tissue survival rate of parathyroid tissue transplantation, and reducing the risk of postoperative hypoparathyroidism.

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical / therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector / substrate / support / scaffold for direct application.

This document discloses compositions and methods involving glycosaminoglycan components. For example, administering a composition comprising a glycosaminoglycan component to an organ before, during, or after ex vivo organ perfusion can improve organ transplantation. These improvements include reduced MMP levels, reduced apoptosis markers, reduced endothelial cell activation, and increased organ function. Such methods and compositions can be used for organ and tissue transplantation, as well as for the storage or transport of acquired organs and tissues.

Compositions and methods relating to glycosaminoglycan components are disclosed. For example, a composition including glycosaminoglycan components are administered to organs before, during, or after ex vivo organ perfusion to improve organ transplantation. The improvements include reduced MMP levels, reduced apoptotic markers, reduced endothelial activation, and increased organ function. Such methods and compositions are useful for organ and tissue transplantation and storage or shipment of harvested organs and tissues.

A three-dimensional oxygen-generating bioscaffold capable of supplying cells with a continuous, controlled, and steady source of oxygen and methods of using such an oxygengenerating bioscaffold to prevent hypoxia-induced damage to cells following transplantation are disclosed. In particular, a collagen-based cryogel bioscaffold having calcium peroxide (CPO) incorporated into its matrix is provided, wherein the CPO produces oxygen upon exposure to water. The collagen-based cryogel is designed with a plurality of macropores capable of encapsulating therapeutic cells for cellular therapy. Methods of producing oxygen-generating bioscaffolds and tissue grafts comprising therapeutic cells contained in such oxygen-generating bioscaffolds as well as their use in cellular therapy are also disclosed.

Compositions and methods relating to glycosaminoglycan components are disclosed. For example, a composition including glycosaminoglycan components are administered to organs before, during, or after ex vivo organ perfusion to improve organ transplantation. The improvements include reduced MMP levels, reduced apoptotic markers, reduced endothelial activation, and increased organ function. Such methods and compositions are useful for organ and tissue transplantation and storage or shipment of harvested organs and tissues.

The present invention discloses the use of anti-angiogenic drugs in improving the retention rate of soft tissue grafts. By using different types of anti-angiogenic drugs to inhibit the early vascularization of soft tissue grafts, the body's immune response to the soft tissue grafts is weakened, thereby reducing inflammation and immune cells, and improving the retention rate of soft tissue grafts.

The invention relates to an application of a soluble epoxide hydrolase inhibitor in the field of transplantation, the soluble epoxide hydrolase inhibitor is TPPU, and the soluble epoxide hydrolase inhibitor is applied in the fields of organ transplantation and tissue transplantation. The TPPU is used for relieving allogeneic mouse heart and skin transplantation immunological rejection, reducing immune cell infiltration in transplantation operation, and inhibiting CD4 + T cell proliferation, CXCR3 chemokine receptor positive and Th1 cell subset proportion. The TPPU inhibits proliferation of primary CD4 + T cells of normal mice and differentiation of Th1 cell subgroups. In organ transplantation and tissue transplantation, the invention provides a single soluble epoxide hydrolase inhibitor TPPU, which can relieve allogeneic mouse heart and skin transplantation immunological rejection, inhibit normal mouse primary CD4 + T cell proliferation and differentiation, and reduce toxic and side effects caused by the use of an immunosuppressant.

The utility model discloses a storage device for skin tissue transplantation, which is characterized in that the storage device comprises a base, a shell and a buffer mechanism, stand columns are arranged on the periphery of the base at equal intervals, a connecting seat is arranged in the shell, and the stand columns are installed in the connecting seat in a sliding mode; the buffering mechanism comprises a plurality of supporting rods slidably installed in the base at equal intervals, the tops of the supporting rods are slidably installed in the shell, the supporting rods are in pin connection with a carrying frame, buffering pieces are arranged on the inner side of the carrying frame at equal intervals, and buffering tables are fixedly installed at one ends of the buffering pieces and are made of elastic materials. A plurality of culture dishes are mounted in the buffer table in an interference fit manner; the buffering mechanism is arranged, the object carrying frame is connected with the buffering table through the buffering piece, vibration of the buffering table on the plane is absorbed through the buffering piece, and the supporting rod slides in the copper pipe, so that vibration of the buffering table on the vertical plane is absorbed through sliding of the supporting rod.

The invention provides a tissue phase homogenizing agent and a preparation method and application thereof, and belongs to the technical field of biological tissue engineering, the homogenizing agent is composed of hydrophilic matrixes (glucose, polyglycerol, poloxamer F127 and polyvinyl alcohol), functional additives (mannose, N-acetylcysteine, sodium hyaluronate and polyethylene glycol) and ultrapure water, and the pH value is 7.0 + / -0.2. Hydrophilic groups and water molecules form a hydrogen bond network, a continuous hydration layer is constructed on a phase interface, phase domain fusion, refractive index homogenization and molecular ordering are achieved, the problem of biological tissue phase homogenization is solved, tissue light transmittance can be improved, the swelling ratio can be stabilized, and the hydrogel has cell proliferation promoting activity and is suitable for tissue transplantation operation and bioengineering tissue preservation.

Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor.

1. The name of the design product: the recess of medical stirring and mixing container. 2. The use of the design product: the whole and recess are used for containing materials to be stirred and mixed, such as medical tissue transplantation materials, and the medical tissue transplantation materials are synthesized after being stirred and mixed. 3. The design points of the design product: the shape. 4. The picture or photo best showing the design points: the perspective view 1.

A tissue transplantation resin tip includes a needle tube for eyeball insertion. The needle tube includes a main body portion that extends linearly. A front end portion is bent with respect to the main body portion and extends linearly, with tissue discharging from the front end. The needle tube length is 25 mm to 50 mm, the front end portion cross sectional shape is oval with a major axis D1 of 0.8 mm to 1.5 mm and a minor axis D2 of 0.5 mm to 1.0 mm. The front end of the front end portion is a bevel surface that extends in a direction substantially perpendicular to the main body portion and has a bevel angle of 50° to 85°. The front end portion hardness is 0.15 N to 0.30 N or less and the center of the needle tube hardness is 0.80 N to 1.50 N.

The present application provides a complex for protecting a cell and / or tissue graft. The complex comprises a cell mixture and a cell / tissue transplant. The cell mixture is used to protect the cell / tissue graft. The transplantation body is at least one of hepatocytes, islet cells, hematopoietic stem cells, adrenal medullary cells, testicular interstitial cells, follicle cells, gland pituitary cells, thyroid tissue blocks, parathyroid gland tissue blocks and thymus tissue blocks. The cell mixture comprises at least one of mesenchymal stem cells, primary hepatocytes, primary fibroblasts, dendritic cells, primary hepatocytes and fibroblasts. The complex not only can solve the problems of oxygen deficit and lack of nutritional factors in the transplantation process of the transplantation body, but also can reduce the immunological rejection reaction of a receptor to an allosome or xenograft after the transplantation of the transplantation body. The invention further provides a preparation method and application of the complex. By utilizing the product, cells or tissues can be transplanted into the spleen, the abdominal cavity or the position below the greater omentum, so that the application range of the transplant is expanded.

Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor.

The application discloses a preparation method of a composition for ovary transplantation and the composition. The composition comprises an antioxidant peptide and a colony stimulating factor. The antioxidant peptide in the composition of the application is attached to the colony stimulating factor, so that the antioxidant peptide can reach a ROS site, the antioxidant peptide can remove active oxygen generated by the ROS site and weaken the oxygen generation capacity of the ROS site, the antioxidant effect is improved, follicle loss is reduced, more follicles are protected, and finally the effect of frozen-thawed ovary tissue transplantation is improved.

Tissue grafts with reduced regenerative potential, methods of preparing such grafts, and related kits and methods of treatment are described. The method may include treating tissue with a digestion solution comprising trypsin, alpha-chymotrypsin (ACT) and optionally ethylenediaminetetraacetic acid (EDTA) to substantially remove one or more susceptible proteins from the tissue. The method may also include washing the treated tissue with a buffer solution and / or with a serine-containing serum. Nerve grafts prepared according to the disclosed methods may inhibit, or lessen (e.g., provide for reduced) neuroma formation and / or axonal outgrowth after implantation.

Provided is a coating-fixing agent for transplanting a cell or a tissue onto the surface of an organ, intestinal membrane, peritoneal membrane, etc. Provided are: a formulation for coating and fixing a graft, the formulation comprising alginate; a formulation kit for coating and fixing a graft, comprising a formulation containing alginate and a divalent or higher valent metal salt in combination; and a method for transplanting a graft, comprising: transplanting the graft to a transplant site of a human or a non-human animal, and coating the graft with alginate.

The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.

To provide methods and compositions relating to isolated mitochondria.SOLUTION: Cells, tissues, or organs can be treated with isolated mitochondria, such as porcine mitochondria, to improve mitochondrial function in the cell, tissue, or organ. The improvements to mitochondrial function include increased oxygen consumption and increased ATP synthesis. Such methods and compositions are useful for cell therapy; organ and tissue transplantation; organ and tissue engineering; and cold storage or shipment of harvested organs, tissues, and cells.SELECTED DRAWING: Figure 1

Disclosed are devices and methods for delivering a sheet of tissue into the eye in such a way that damage to the tissue is minimized, damage to the eye during insertion and manipulation of the tissue is minimized, and the tissue is released and delivered in a precise and controlled fashion.

To provide a technique relating to a method for treating anodontia by utilizing the differentiation induction inherent in a tooth organ, instead of utilizing surgical tissue transplantation.SOLUTION: Provided is a medicinal composition to be topically administered for tooth regeneration therapy, the composition comprising an RNA molecule targeting USAG-1 or a nucleic acid molecule capable of yielding the RNA molecule and a pharmaceutically acceptable carrier.SELECTED DRAWING: None

The invention relates to a pH sensor that can be embedded within a flap, allows wired or wireless operation, is biocompatible, does not require an additional power source thanks to its Schottky diode structure, and is capable of detecting the increase in tissue acidity caused by changes in blood flow and ischemia through ion exchange and closed-circuit currents. The pH sensor subject to the invention is suitable for use in the healthcare field, in areas dealing with tissue transplantation such as plastic surgery, hand surgery, and transplant surgery.

The invention relates to the field of fertility preservation and protection before adolescence, in particular to a transition culture method before immature testicular tissue transplantation. In a transition culture process before immature testicular tissue transplantation, coexistence states (such as FSH and testosterone continuously exist in a male body) of various growth factors and hormones in an in-vivo microenvironment are simulated, or in-vivo physiological dynamic changes are simulated. According to the transition culture method disclosed by the invention, the huge environmental difference caused by transplanting the testicular tissue before adolescence to the mature testicular tissue is reduced, the proliferation of spermatogonium and the maturation of supporting cells are remarkably promoted, the survival rate of the spermatogonium after transplantation is improved, and a foundation is laid for spermatogenesis after transplantation.

The present disclosure provides a mechanically-actuated tool for cutting a tissue graft having a hollow core and methods for use thereof. A portion of a biological structure, such as a nerve, is attached to the hollow core to form an implantable neural graft assembly. The tool has a cutter mechanism and a grasper mechanism. The grasper mechanism has one or more component(s) that open and close via an actuation mechanism, like a handle, and rotate via a controller component, like a rotatable wheel. The cutter mechanism may be a cutting tube component that harvests the tissue graft. The tool may also have an ejector mechanism to remove the tissue graft as part of the implantable neural graft assembly. Such devices and methods are particularly suitable for treating neuromas and other neural regeneration procedures.

The invention disclosed herein provides methods and materials designed to improve organ transplantation outcomes. Embodiments of the invention include methods for administering the drug belumosudil to patients who have undergone an organ or other tissue transplantation (e.g., transplantation of a solid donor organ such as a kidney and / or receiving an infusion of donor stem cells such as CD34+ cells). In these methods, transplantation patients to whom belumosudil is administered are selected to be those not suffering from graft versus host disease (GVHD).

A method of preparing a nerve graft includes submerging a nerve graft in a solution including FK506 and a solvent to promote incorporation of FK506 into the nerve graft. A tissue graft includes nerve tissue and FK506 incorporated within the nerve tissue. In the tissue graft, the FK506 is free of hydrogel and not encapsulated.

Macroencapsulation devices for transplanting cells or tissues are provided. In addition, macroencapsulation devices for local delivery of a drug to establish local immunosuppressive therapy are provided.

The invention belongs to the technical field of cell construction, and particularly relates to a mouse melanoma cell construction method which is characterized by comprising the following steps: sampling and preparing a sample; sampling; performing secondary screening; performing tissue culture; performing tissue transplantation; tumor formation; the method comprises the following steps: carrying out in-vitro culture, namely selecting a tumor-bearing mouse, killing the tumor-bearing mouse, carrying out super clean bench sterile operation on suspension cells, carrying out in-vitro culture by using DMEM + 20% FBS, observing whether the cells can be stably inherited or not, carrying out in-vitro culture for 7-10 days by using DMEM + 10% FBS culture after the morphology is stable, carrying out stable passage, stable shape and uniform cell morphology, digesting the cells, centrifuging at 3000 revolutions for 5 minutes, collecting the cells, adding PBS for resuspension, and carrying out in-vitro culture by using DMEM + 10% FBS culture after the morphology is stable. Centrifuging the cells at 3000 revolutions for 5 minutes, and discarding the supernatant to obtain a cell precipitate; finally, the cell precipitates are subjected to library building and sequencing for STR identification, subcutaneous tumors are inoculated on C57 mice at the same time, and the subcutaneous tumors expressing melanin are obtained. According to the invention, a completely new mouse melanoma cell line is constructed from another new scheme, and the mouse melanoma cell line is named as an MP306 cell line.